作為商業發展副總裁，林劍將負責領導堯唐生物BD、公共關系及投資者關系部的整體管理，根據公司總體戰略發展需要，負責制定及執行伙伴關系及企業投資策略、建立創新能力以及整體相關業務生態系統，通過合作為公司帶來優質的研發及商業資源和投資機會，推動公司業務增長。

林劍本科畢業于山東大學國家生物基地班生物技術專業，擁有中國科學院生物技術與醫藥專業碩士學位和中歐商學院MBA，法國蒙彼利埃大學就讀醫藥健康管理學博士。

在加入堯唐生物之前，林劍曾在康寧杰瑞擔任商務合作部門負責人，負責公司全球BD以及戰略聯盟管理業務；并曾服務于多家跨國制藥企業包括日本衛材、勃林格殷格翰、強生和諾華等公司，在商務拓展、戰略制定、投資并購、聯盟管理、市場銷售及產品管理領域積累了豐富的經驗。

林劍在生物制藥行業經驗超過15年，他曾主導并參與20多項國內及全球對外合作，涵蓋license許可交易、戰略合作以及股權交易等多種商業模式，總交易金額超過10億美金，維護并管理數十家全球合作伙伴關系包括輝瑞、賽諾菲、德國默克、中國石藥、先聲、以嶺及京東健康等知名企業。

As Vice President of Business Development, Colin Lin will be responsible for leading the overall BD, public relations, and investor relations departments in Yoltech, he will bring high-quality R&D and commercial resources and investment opportunities to the company through various of partnership including out-licensing and financing,  to empower pipeline competence and promote business growth.

Colin started career from Novartis internship and then got MT offer from Johnson & Johnson Medical. Led multiple healthcare licensing, strategy, and equity projects in Eisai. Acted as brand owner of company’s best selling product in Boehringer Ingelheim. As head of BD at Alphamab, led 10+ deals, including inlicensing, global out-licensing, and multi-spectrum deals (total deal size nearly $1.0 Bn). 

Colin has 15 years of  pharmaceutical industry experience in business development, strategy & alliance management, etc. Led to complete a number of licensing deals, strategic cooperation and equity investment projects, owned a wealth of experience across all parts of business development value chain, familiar with various of disease fields. He is PhD candidate in montpellieruniversity, received a master's degree in biomedicine from the China Academy of Science and a MBA degree in CEIBS.